ES2090858T3 - Composicion que comprende una fuente de acido graso omega-3 y un estimulador de glutation para el tratamiento de trastornos inmunes e infecciones viricas. - Google Patents

Composicion que comprende una fuente de acido graso omega-3 y un estimulador de glutation para el tratamiento de trastornos inmunes e infecciones viricas.

Info

Publication number
ES2090858T3
ES2090858T3 ES93301861T ES93301861T ES2090858T3 ES 2090858 T3 ES2090858 T3 ES 2090858T3 ES 93301861 T ES93301861 T ES 93301861T ES 93301861 T ES93301861 T ES 93301861T ES 2090858 T3 ES2090858 T3 ES 2090858T3
Authority
ES
Spain
Prior art keywords
glutation
stimulator
source
treatment
omega
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93301861T
Other languages
English (en)
Inventor
David A Mark
W Bruce Rowe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transcend Therapeutics Inc
Original Assignee
Transcend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transcend Therapeutics Inc filed Critical Transcend Therapeutics Inc
Application granted granted Critical
Publication of ES2090858T3 publication Critical patent/ES2090858T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EL PRESENTE INVENTO PREVE UN METODO PARA TRATAR UNA INFECCION VIRAL O DESORDEN INMUNOLOGICO, ASI COMO LAS COMPOSICIONES DEL MISMO. EL METODO DE TRATAMIENTO COMPRENDE LA ADMINISTRACION A UN PACIENTE QUE TIENE UNA INFECCION VIRAL O UN DESORDEN INMUNOLOGICO, UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE UNA COMPOSICION QUE INCLUYE UN ESTIMULADOR GLUTATIONE INTRACELULAR Y UNA FUENTE DE ACIDO GRASO OMEGA - 3.
ES93301861T 1992-04-08 1993-03-11 Composicion que comprende una fuente de acido graso omega-3 y un estimulador de glutation para el tratamiento de trastornos inmunes e infecciones viricas. Expired - Lifetime ES2090858T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/865,288 US5214062A (en) 1992-04-08 1992-04-08 Method and composition for treating immune disorders, inflammation and chronic infections

Publications (1)

Publication Number Publication Date
ES2090858T3 true ES2090858T3 (es) 1996-10-16

Family

ID=25345142

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93301861T Expired - Lifetime ES2090858T3 (es) 1992-04-08 1993-03-11 Composicion que comprende una fuente de acido graso omega-3 y un estimulador de glutation para el tratamiento de trastornos inmunes e infecciones viricas.

Country Status (7)

Country Link
US (1) US5214062A (es)
EP (1) EP0567216B1 (es)
JP (1) JPH0625006A (es)
AU (1) AU663923B2 (es)
CA (1) CA2093163A1 (es)
DE (1) DE69304118T2 (es)
ES (1) ES2090858T3 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
DK0494405T3 (da) * 1991-01-10 1996-11-18 Transcend Therapeutics Inc Anvendelse af thiazolidin-4-carboxylatderivater til behandling af lungesygdomme
ATE137968T1 (de) * 1991-09-30 1996-06-15 Transcend Therapeutics Inc Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia
AU5040493A (en) * 1992-11-30 1994-06-09 Transcend Therapeutics, Inc Method for treating systemic inflammatory response syndrome
FR2711529B1 (fr) † 1993-10-28 1996-07-05 Clintec Nutrition Cy Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme.
US5447712A (en) * 1993-12-09 1995-09-05 Free Radical Sciences Method of reducing cyclophosphamide induced hemorrhagic cystitis
US5397778A (en) * 1994-02-25 1995-03-14 New England Deaconess Hospital Corporation Enteral formulations for treatment of inflammation and infection
JPH10500937A (ja) * 1994-02-25 1998-01-27 ニュー イングランド ディーコネス ホスピタル コーポレイション セサミン系リグナンの抗炎症及び感染防護効果
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
DE19629433A1 (de) * 1996-07-22 1998-01-29 Hoechst Ag Omega-3-fettsäurenenthaltende Zubereitung aus Mikroorganismen als Prophylaktikum bzw. Therapeutikum gegen parasitäre Erkrankungen beim Tier
DE19652586A1 (de) * 1996-12-17 1998-06-18 Biotechnolog Forschung Gmbh Dhc-Peptid und Mittel
WO1998030228A1 (en) * 1997-01-13 1998-07-16 Emory University Compounds and their combinations for the treatment of influenza infection
US6055936A (en) * 1997-01-21 2000-05-02 Collin; Peter Donald Sea cucumber carotenoid lipid fractions and process
US5776463A (en) * 1997-02-19 1998-07-07 Arginteanu; Ronit Method of reducing stress and circulatory heart disease with freeze-dried borage petal extracts
US6197749B1 (en) * 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
US20030203006A1 (en) * 1997-10-29 2003-10-30 Ajinomoto Co. Inc. Immunomodulator
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
WO2000006192A1 (fr) * 1998-07-30 2000-02-10 Morinaga Milk Industry Co., Ltd. Agents ameliorant la fonction hepatique
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US7012086B1 (en) 2000-06-30 2006-03-14 The Foundation For Innovative Therapies, Inc. Treatment of retrovirus induced derangements with niacin compounds
US6476072B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating menstrual pain by enhancing the effectiveness of the human immune system
ATE556706T1 (de) * 2001-03-23 2012-05-15 Luitpold Pharm Inc Fettalkohol-arzneimittel-konjugate
AU2002303164A1 (en) * 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
US20050054730A1 (en) * 2001-03-27 2005-03-10 The Regents Of The University Of California Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
US20080096872A1 (en) * 2004-12-22 2008-04-24 Friedman Robert S Composition for Treatment of Pain Specification
US20090068253A1 (en) * 2005-09-06 2009-03-12 Guilford F Timothy Method for the treatment of infection with hhv-6 virus and the amelioration of symptoms related to virus using liposomal encapsulation for delivery of reduced glutathione
US20070105782A1 (en) * 2005-10-07 2007-05-10 Board Of Trustees Of Southern Illinois University Protectant Combinations for Reducing Toxicities
US20070149617A1 (en) * 2005-11-14 2007-06-28 Deckelbaum Richard J Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
DE102005062417A1 (de) * 2005-12-27 2007-08-23 Korth, Ruth-Maria, Dr.med. Kompositionen mit spezifischen und unspezifischen Lipidantagonisten
US11039997B2 (en) 2005-12-27 2021-06-22 Ruth-Maria Korth Cosmetic, dermatic, protective compositions comprising phospholipids, lecithins with peptides and at least one acetylating compound
CN100434062C (zh) * 2006-08-28 2008-11-19 卢小明 L-2-氧代硫氮杂戍环烷-4-羧酸及其酯类衍生物作为皮肤药妆品的应用
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
EP2978307B1 (en) 2013-03-28 2018-12-26 The Trustees of Columbia University in the City of New York Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1476624A (en) * 1973-05-30 1977-06-16 Cepbepe Tranquiliser medicaments
EP0087865B1 (en) * 1982-03-01 1986-10-01 Efamol Limited Pharmaceutical composition
US4710489A (en) * 1985-04-22 1987-12-01 Cornell Research Foundation, Inc. Glutathione delivery system
HU200177B (en) * 1985-06-18 1990-04-28 Biogal Gyogyszergyar Process for producing thiazolidinecarboxylic acids and pharmaceutical compositions comprising such compounds
US5053387A (en) * 1987-02-20 1991-10-01 Shriners Hospitals For Crippled Children Omega-3 fatty acids in traumatic injury treatment
GB8918294D0 (en) * 1989-08-10 1989-09-20 Efamol Holdings Pharmaceutical compositions
BR9105986A (pt) * 1990-02-05 1992-11-10 Univ Texas Formulacao de liberacao por tempo de vitaminas,minerais e outros suplementos beneficos
US5089268A (en) * 1990-05-02 1992-02-18 Katz David P Egg phosphatide lipid emulsions altered for a specific therapeutic fatty acid composition
ES2106096T3 (es) * 1991-02-04 1997-11-01 Nestle Sa Procedimiento para asegurar glutation intracelular adecuado en el tejido.
GB9116054D0 (en) * 1991-07-24 1991-09-11 Efamol Holdings Preparation of fatty acid medicaments

Also Published As

Publication number Publication date
AU663923B2 (en) 1995-10-26
EP0567216B1 (en) 1996-08-21
DE69304118D1 (de) 1996-09-26
DE69304118T2 (de) 1997-03-06
JPH0625006A (ja) 1994-02-01
US5214062A (en) 1993-05-25
AU3409293A (en) 1993-10-14
EP0567216A1 (en) 1993-10-27
CA2093163A1 (en) 1993-10-09

Similar Documents

Publication Publication Date Title
ES2090858T3 (es) Composicion que comprende una fuente de acido graso omega-3 y un estimulador de glutation para el tratamiento de trastornos inmunes e infecciones viricas.
DE69533112D1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
BR9307104A (pt) Preparações reforçadora de mecanismos de defesa de hospedeiros e migrante com pico único b-glicano hidrossolúvel métodos para produzir uma preparação reforçadora de meanismos de defesa de hospedeiros para impedir infecção em um mamífero para estimular o reparo e cura de uma ferida e para estimular a proliferação de plaquetas composição farmacêutica e método para tratar infecção em mamíferos
SE8504967D0 (sv) A pharmaceutical composition and a method of treating the body
ES541103A0 (es) Procedimiento de obtencion de una composicion para el trata-miento de infecciones virales
ES2177780T3 (es) Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau.
ES2058799T3 (es) Composiciones estabilizadas que contienen factor de crecimiento epidermico.
MX9302160A (es) Composiciones farmaceuticas del interferon de leu cocito humano concordante.
ES2106794T3 (es) Utilizacion del inositol-trifosfato para el tratamiento de inflamaciones.
MX2023006146A (es) Composiciones bacterianas diseñadas para tratar la enfermedad de injerto contra huésped.
ES2174921T3 (es) Inhibidores de la proteasa del vih.
WO2022010813A3 (en) Enhancing immune responses through targeted antigen expression
WO2022159501A3 (en) Methods and compositions for treating neurodegenerative diseases
BG100599A (en) Antiviral form and therapeutical method
BRPI0414139A (pt) métodos e composições para tratar infecções por herpes
ES2078251T3 (es) Sistema para la distribucion regulada de agentes activos y proceso para su preparacion.
MX9304925A (es) Composiciones terapeuticas contra el cancer para profilaxis o para el tratamiento de cancer.
CA2150234C (en) COMBINATION OF ATOVAQUONE AND PROGUANIL FOR THE TREATMENT OF PROTOZOA INFECTION
SE8403659L (sv) Synergistiska farmaceutiska kompositioner
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
ZA202210027B (en) Compositions of vitamin a palmitate, processes for their preparation, uses and methods comprising them
ATE167628T1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
BR0211545A (pt) Método e composição para tratamento de hipertensão ocular e glaucoma
ES2148268T3 (es) Composicion farmaceutica para prevenir o tratar fracturas de huesos.
EP1374873A4 (en) USE OF N-ACETYL-D-GLUCOSAMINE IN THE PRODUCTION OF A MEDICINAL PRODUCT FOR SUPPRESSING THE SIDE EFFECTS OF RADIATION THERAPY AND CHEMOTHERAPY

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 567216

Country of ref document: ES

FG2A Definitive protection

Ref document number: 567216

Country of ref document: ES